Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Usana Health Sciences (USNA) Receivables (2016 - 2026)

Usana Health Sciences has reported Receivables over the past 6 years, most recently at $9.7 million for Q2 2026.

Quarterly Receivables changed N/A to $9.7 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Apr 2026, changed N/A year-over-year, with the annual reading at $12.4 million for FY2026, N/A changed from the prior year.
Receivables was $9.7 million for Q2 2026 at Usana Health Sciences, down from $12.4 million in the prior quarter.
Over five years, Receivables peaked at $12.4 million in Q1 2026 and troughed at $9.7 million in Q2 2026.